don haka ga Jerin Manyan Kamfanonin Biotech da ke Jamus waɗanda aka ware su bisa jimilar kuɗin shiga.
| S / N | Company Name | Jimlar Kudaden Shiga (FY) | Yawan ma'aikata |
| 1 | Morphosys AG girma | $ 401 Million | 615 |
| 2 | Brain Biotec Na | $ 45 Million | 279 |
| 3 | Formycon Ag | $ 42 Million | 131 |
| 4 | Biofrontera Ag Na | $ 37 Million | 149 |
| 5 | Vita 34 Ag Na | $ 25 Million | 116 |
| 6 | Heidelberg Pharma AG girma | $ 10 Million | 84 |
| 7 | Medigene Ag Na | $ 10 Million | 121 |
| 8 | 4Sc Ag Inh. | $ 3 Million | 48 |
Morphosys AG girma
MorphoSys AG ana kasuwanci dashi a shafukan yanar gizo na kasuwanci daban-daban. Kamfanin yana mai da hankali kan ganowa, haɓakawa, da isar da sabbin magungunan cutar kansa. MorphoSys yana hidima ga abokan ciniki a duk duniya.
BRAIN Biotech AG girma
BRAIN Biotech AG kamfani ne na fasaha, wanda ke shiga cikin haɓakawa da kasuwanci na bioactives, mahadi na halitta, da enzymes na mallaka. Yana aiki ta ɓangaren BioScience da BioIndustrial.
Sashin BioScience yana aiki akan enzymes da ƙananan ƙwayoyin cuta; kuma yana aiki tare da abokan aikin masana'antu. Sashin BioIndustrial yana ma'amala da samfuran bioproduct da kasuwancin kayan kwalliya. Holger Zinke, Jüngen Eck, da Hans Günter Gassen ne suka kafa kamfanin a ranar 22 ga Satumba, 1993 kuma yana da hedikwata a Zwingenberg, Jamus.
Formycon
Formycon jagora ne, mai zaman kansa mai haɓaka ingantattun magungunan biopharmaceutical, musamman biosimilars. Kamfanin ya mai da hankali kan jiyya a Ohhmalmology, Imcuntology da kuma kan sauran dabaru na III da kuma shirye-shiryen karatun asibiti.
Tare da biosimilars ɗin sa, Formycon yana ba da babbar gudummawa ga samar da yawancin marasa lafiya da dama tare da samun magunguna masu mahimmanci da araha. Formycon a halin yanzu yana da biosimilars guda shida a cikin haɓakawa. Dangane da gogewar da yake da ita a cikin haɓaka magungunan biopharmaceutical, kamfanin kuma yana aiki akan haɓaka maganin COVID-19 FYB207.
Biofrontera Ag Na
Biofrontera AG wani kamfani ne na biopharmaceutical wanda ya ƙware a haɓaka da siyar da magungunan fata da kayan kwalliyar likita. Kamfanin na tushen Leverkusen yana haɓakawa da kasuwannin sabbin samfuran don magani, kariya da kula da fata.
Mahimman samfuransa sun haɗa da Ameluz®, maganin rubutaccen magani don maganin ciwon daji na fata wanda ba melanoma ba da kuma abubuwan da ke faruwa. An sayar da Ameluz® a cikin EU tun daga 2012 kuma a cikin Amurka tun daga Mayu 2016. A Turai, kamfanin kuma yana sayar da jerin Belixos® dermocosmetic, samfurin kulawa na musamman don lalata fata. Biofrontera ɗaya ne daga cikin ƴan Jamusanci kamfanin harhada magunguna don karɓar amincewar Turai ta tsakiya da Amurka don maganin da aka haɓaka a cikin gida. An kafa ƙungiyar Biofrontera a cikin 1997 kuma an jera su akan musayar hannun jari na Frankfurt (Prime Standard).
Vita 34 Ag Na
An kafa shi a Leipzig a cikin 1997 a matsayin farkon jini mai zaman kansa bank a Turai, Vita 34 ne mai cikakken kewayon maroki na cryo-tsare da kuma samar da dabaru don tattara jini, da shiri da kuma ajiyan kara Kwayoyin daga umbilical igiyar jini da nama.
Kwayoyin tushe sune kayan tushe mai mahimmanci don maganin ƙwayoyin cuta. Ana kiyaye su da rai a yanayin zafi na kusan digiri 180 don samun damar yin amfani da su a cikin iyakokin jiyya, lokacin da ake bukata. Fiye da abokan ciniki 230.000 daga Jamus da wasu ƙasashe 20 sun riga sun buɗe asusun ajiyar kwayar halitta tare da Vita 34, don haka samar da lafiyar 'ya'yansu.
Heidelberg Pharma AG girma
Heidelberg Pharma AG kamfani ne na biopharmaceutical wanda ke aiki a fagen ilimin oncology. Kamfanin yana mai da hankali kan haɓakar Antibody Drug Conjugates (ADCs) don kula da cututtukan oncological. Heidelberg Pharma's abin da ake kira ATACs sune ADCs bisa fasahar ATAC da ke amfani da Amanitin a matsayin sinadari mai aiki. Tsarin nazarin halittu na aikin gubar Amanitin yana wakiltar sabuwar ka'idar warkewa.
Ana amfani da wannan dandamali na mallakar mallaka don haɓaka ATACs na warkewa na Kamfanin da haɗin gwiwar ɓangare na uku don ƙirƙirar ƴan takarar ATAC iri-iri. Dan takarar jagoran mai mallakar HDP-101 shine BCMA-ATAC don myeloma da yawa. Ƙarin ƴan takarar ci gaba na asali sune HDP-102, CD37 ATAC don Non-Hodgkin lymphoma da HDP-103, PSMA ATAC don ciwon daji na prostate mai jurewa.
Kamfanin da kuma reshensa na Heidelberg Pharma Research GmbH yana cikin Ladenburg kusa da Heidelberg a Jamus. An kafa shi a cikin Satumba 1997 a matsayin Wilex Biotechnology GmbH a Munich kuma an canza shi zuwa WILEX AG a 2000. A cikin 2011, an sami reshen Heidelberg Pharma Research GmbH kuma bayan sake fasalin, ofishin rajista na WILEX AG ya koma daga Munich zuwa Ladenburg kuma Canjin ya koma Heidelberg Pharma AG.
Reshen Heidelberg Pharma GmbH yanzu ana kiransa Heidelberg Pharma Research GmbH. Heidelberg Pharma AG an jera a kasuwar musayar hannayen jari ta Frankfurt a cikin Kasuwar Kayyadewa / Prime Standard.
